Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2004

View Archived Issues

A preclinical trial suggests that histamine protects the liver against LPS-induced damage

Therapeutic benefits of Pegasys plus ribavirin in HCV-infected patients

Synthetic truncated PSP94 for metastatic hormone-resistant prostate cancer patients

VaxGen anthrax vaccine candidate prepares to enter phase II trial

Preclinical, preliminary clinical data on GW-280430A, a nondepolarizing neuromuscular blocking agent

Benefits of statins and ACE inhibitors in coronary heart disease

Sinapultide equivalent to poractant alfa in the prevention of RDS

ABI-793 shows promise, complications in renal transplant model

TAK-559, a PPARalpha/gamma coagonist for the treatment of dyslipidemia

Atherosclerosis in LDLR mice inhibited by PPARdelta ligand GW-0742

Novel cytotoxic agent effective against chemotherapy-resistant ovarian carcinoma

Selective acetylcholinesterase inhibitor effective against bladder voiding dysfunction

New data on Fujisawa's histone deacetylase inhibitor FR-901228

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: MacroChem

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Newron

R&D highlights from the 3rd Annual Global Biotech Forum for Investing & Partnering: Munich Biotech

Novel BH3-derived proapoptotic peptides developed by Dana Farber researchers

New IKK inhibitors and their use reported by Aventis Pharma

Novo Nordisk claims the preparation and use of novel PPARdelta agonists

New ORL1 receptor modulators with potential in anxiety and other disorders

CV Therapeutics describes adenosine A3 agonists for cancer and neutropenia therapy

Two series of histamine H4 antagonists prepared and tested at Janssen

Phase III results of R-1549 in ovarian cancer disappoint

European CPMP recommends broader indication for Remicade in early RA

Phase III trial of Tarceva in NSCLC meets endpoints

Genmab licenses GT43 cancer target from Ganymed

CRX-675 enters phase I trial for seasonal allergic rhinitis

ViRexx Medical receives grant to fund phase I trial of Occlusin

Levitra receives Japanese approval

Phase II/III trial of Fibrillex cleared to continue

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...